RxDoctor Payments Data

Heather Turner

Nurse Practitioner · New Castle, INNPI 1710271606

Payments from drug & device makers

$3,431in general payments, 2019–2025

Across 159 payments — averaging $21.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$893
  • AbbVie$693
  • GSK$257
  • Lilly USA, LLC$253
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$215
  • Novo Nordisk$200
  • plus $921 from 18 others

What the payments were for

  • Food & beverage$3,431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,431 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$82,993
OzempicSemaglutide71$75,517
FarxigaDapagliflozin Propanediol59$63,298
JardianceEmpagliflozin51$53,896
TrulicityDulaglutide34$44,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$35,926
RybelsusSemaglutide31$35,182
XareltoRivaroxaban28$25,963
GemtesaVibegron20$25,037
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$20,860
MyrbetriqMirabegron20$17,017
VraylarCariprazine Hcl12$16,819
EliquisApixaban19$13,312
Combivent RespimatIpratropium/Albuterol Sulfate12$11,528
JanuviaSitagliptin Phosphate21$11,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$253$127,80793 claims
Novo NordiskOzempic, Rybelsus$200$110,700102 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$893$87,025101 claims
GSKTrelegy Ellipta, Breo Ellipta$257$44,22860 claims
Johnson & JohnsonXarelto$126$25,96328 claims
Sumitomo Pharma America, Inc.Gemtesa$41$25,03720 claims
Astellas Pharma US IncMyrbetriq$14$17,01720 claims
AbbVieVraylar$693$16,81912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in New Castle

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →